IBSA USA Renews Partnership With Professional Golfer Aza Muñoz to Promote Tirosint®-SOL

5 June 2024

IBSA USA has renewed its partnership with professional golfer Azahara (Aza) Muñoz to promote Tirosint®-SOL oral solution, a unique liquid hypothyroidism treatment, through the 2025 golf season. As part of the multi-year renewal, Muñoz will continue to serve as a spokesperson at in-person events, in videos, and on social media to promote the brand while wearing the Tirosint-SOL logo on the sleeve of her golf attire.

Muñoz, who has Hashimoto’s thyroiditis that results in hypothyroidism, has found relief since she began taking Tirosint-SOL and regained control over her hypothyroid symptoms. She attributes her restored energy and improved symptom relief to this innovative treatment option.

“Using Tirosint-SOL has been transformative for me — it has helped me get back in full swing both on and off the golf course. I’ve experienced significant improvements in my energy levels and overall well-being,” said Muñoz. “I now have the energy to keep up with my child’s active lifestyle.”

Tirosint-SOL was the first oral liquid formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypothyroidism, a condition in which a person cannot produce enough thyroid hormone to meet their body’s needs. In November 2023, the FDA approved two new label updates for Tirosint-SOL, offering patients increased flexibility in administration. As a result, Tirosint-SOL is now the only FDA-approved levothyroxine therapy with no labeled interaction with proton pump inhibitors (PPIs) and is the only FDA-approved levothyroxine therapy that can be administered 15 minutes before eating breakfast.1

“We are delighted to renew our partnership with Aza Muñoz, whose personal journey with hypothyroidism underscores the efficacy of Tirosint-SOL,” said Michael Scully, Head of Commercial Operations, IBSA USA. “The recent label changes further solidify Tirosint-SOL’s position as a unique treatment option for individuals living with hypothyroidism.”

Tirosint-SOL has 15 dosing strengths, including unique 13, 37.5, 44, and 62.5 microgram dosing options, the widest range of doses of any levothyroxine therapy available in the U.S. It is made with only three ingredients  levothyroxine, glycerol, and water1 — and is widely available in retail pharmacies.

 

Source:businesswire.com